Critical considerations in the formulation development of parenteral biologic drugs.

Clicks: 278
ID: 79605
2020
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Biopharmaceuticals, unlike chemically synthesized small-molecule drugs, are marginally stable, with most of them requiring 3D structures to retain their activity and/or potency. This implies challenges to formulate these molecules for a shelf life >2 y of and also to minimize the cost of goods for manufacturing. Patient compliance has become a key consideration in the design and development of suitable dosage forms in the modernized world. Thus, here we describe different classes of biological therapeutic, with an emphasis on molecular properties, formulation challenges, and development strategies. We also present statistics on the different classes of approved biologic drugs and dosage forms.
Reference Key
muralidhara2020criticaldrug Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Muralidhara, Bilikallahalli K;Wong, Marcus;
Journal Drug discovery today
Year 2020
DOI
S1359-6446(20)30002-7
URL
Keywords
blood pressure heart rate exercise cardiac rehabilitation cardiovascular diseases. virtual reality exposure therapy

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.